Alex C Sapir appointed as Fulcrum Therapeutics’ CEO
Clinical stage biopharmaceutical company, Fulcrum Therapeutics, has announced the appointment of Alex C Sapir as chief executive officer and president effective, 1 July 2023. Sapir will also join the company’s board of directors, alongside Robert Gould PhD, Fulcrum’s interim CEO who will continue to serve on the board following the transition.
Previously Sapir worked as a part-time special advisor to the interim president and CEO at Fulcrum. He has over two decades of industry experience and has recently served as CEO of ReViral Ltd, which was acquired by Pfizer in 2022.
Dr Gould commented: “We are delighted to welcome Alex as our new CEO. Alex brings a wealth of experience leading innovative companies through periods of strategic change, and a strong track record of delivering growth and enhanced value to patients, employees and stockholders. We have great confidence in his ability to shepherd our company through the next phase of our journey.”
Speaking on his new role, Sapir added: “I am both honoured and excited to lead Fulcrum at this pivotal stage. Fulcrum’s progress to date is a testament to what can be achieved when a commitment to patients and visionary science come together. I look forward to building on this strong foundation as we work to advance and expand our pipeline to deliver on its unique promise for patients.”